CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Methylphenidatedrug
Likely dose
Methylphenidate 0.3 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02227056
NCT02227056Phase 2Completed
CompareCT.gov

Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population

Loewenstein Hospital·interventional·Posted Aug 27, 2014·Updated Feb 26, 2019

In Brief

A Phase 2 clinical trial evaluating Methylphenidate for Acquired Brain Injury. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the influence of Methylphenidate in pediatric acquired brain injury population, regarding ecologic (every day) function. It is hypothesized that the function with treatment will improve when compared to function without treatment in the same patient. Improvement is expected by shortening time of execution in each specific task and by reduction of the amount of assistance needed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Brain Injury
CountriesIsrael
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 27, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 30, 2017
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.8 years ago

Interventions

Methylphenidatedrug

On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage